Obesity drug CagriSema will be important product

Copenhagen, Denmark – Nine noralymous challenge the results of refusing the candrator’s conducting results of the soft-hyped-hyped

COU LERS FRUERGAARD ​​Jørgense on the Thursday’s price recounted the weight constantly shown a substance wight collection, but he said to the late Pike “encouraged.”

“We’re having a lot of cagrisema”, he told the annual stake convision in copenhagen, Denmark.

“It will be an important product for us.”

CagRisema is a combination of cachylintida – a housemate loss treatment, as an amylin analog – and semagluities, the active ingredient in wegovy.

Title results from a RedefinY-2 late stage test released Before the month has shown that cagrisema helped the obese patients with Type 2 diabetes lost 15.7% of their weight, compared with the minimum. This was under the percentage of the weight weight’s weight feeding.

A trait of last-lasting trial first Posted In December showed the drug helps or diabetitation or not to write-2, lower their weight from 22.7 weeks, as well as below 25% expected.

All of the two results will delete a significance price of investors to find a higher alternative to the company injection of the company’s existing Eli lily Zepbound, both glp-1 medication, have been tracked. The action of a darling time is now over 50% from their 2024 high.

Danish Pharmactic Giants once on Thursday, as the shareholders originate for lighter sounds and tactions and tacties in an offer to cause less than dramatic

Fruerger Jørger recognized, in particularly accomplishments correctly argue the flexible design, which raised to the highest dose after 68 weeks.

“22.7% is not 25%, so some people smooth you hear from this,” saying about the potential that’s “continued overally period.

Novo Nordisis is now a new phase test 3, doubt redefine 11, who would like to “explore the caged’s potential, the CEO has thrown.

I am from the weight loss industry remain divided on the wider applications and obesity results al dogged the total weight reduction. In a note previously prepared this month, global mouth search that he had cultivated “slightly more cautiously about differentiation” and diabetes the last results of cagrisema.

However, LonTost, analytics of Equity Pharma in Sydbank, she said CNBC next week that have been needed for a different range of ounces and tolerable health treatments, even associates as a sickness of sleep apney.

“It is clear that there is a lot of market beef, he also takes a carbolic of the products that achieves different need: FrugerAard Jørgense noticed.